

Clinical Trial Investigative Site Network Market Size, Share & Trends Analysis Report By Therapeutic Areas (Oncology, CNS), By Phase (Phase I, III), By End-use (Sponsor, CRO), By Region, And Segment Forecasts, 2022 - 2030

https://marketpublishers.com/r/C1EDABC88200EN.html

Date: October 2022

Pages: 275

Price: US\$ 5,950.00 (Single User License)

ID: C1EDABC88200EN

Abstracts

This report can be delivered to the clients within 3 Business Days

Clinical Trial Investigative Site Network Market Growth & Trends

The global clinical trial investigative site network market size is expected to reach USD 12.5 billion by 2030, registering a CAGR of 6.0% over the forecast period, according to a new report by Grand View Research, Inc. Growing investments in pharmaceutical R&D, increasing demand for new therapies and complications associated with site management of clinical trials are some of the major factors driving the growth of the industry. There has been a consistent rise the clinical trials in the last 5 years. For instance, according to ClinicalTrials.gov, over 262,298 trials were registered in 2018, whereas as of September 2022, over 399,518 trials were registered. The clinical trials are expected to grow even further as the funding for research improves.

This is expected to propel the growth of the industry post-pandemic. There is a growing focus on reducing the cost associated with clinical research. Hiring a clinical trial investigative site network supports the regulatory function, improves the enrollment of participants, assists in data management, and quality assurance. It increases process compliance, reduces process issues with each trial, and helps with faster trial initiations, and shorter trial timelines. These factors are supporting the demand for clinical investigative site networks. The governments are actively trying to improve R&D by providing tax deductions. For instance, in January 2022, the Indian government stated



that it is providing a weighted average tax deduction of up to 200% in R&D.

Such initiatives are expected to improve the R&D activities on drugs and thus support industry growth. According to the IQVIA, report on oncology trends, clinical trials for cancer have been increasing for the last 10 years. For instance, in 2011, 1,242 trials were registered for cancer, and as of 2021, 2,335 trials were registered for cancer. The number of clinical trials for cancer is expected to rise even further owing to the growing prevalence of the disease. This is expected to improve the demand for clinical investigative site networks for cancer clinical trials post-pandemic.

Clinical Trial Investigative Site Network Market Report Highlights

Based on therapeutic areas, the oncology segment held the largest revenue share in 2021. The growing number of clinical trials for cancer is one of the major factors supporting the segment growth

The phase III segment led the industry in 2021 with the maximum revenue share as this phase includes a greater number of patients than other phases, thus supporting the demand for clinical investigative site network

Based on end-use, the Contract Research Organizations (CROs) segment is anticipated to witness the fastest CAGR over the forecast period

This is owing to the increasing number of partnerships among site networks and CROs for clinical studies

Asia Pacific is anticipated to register the fastest CAGR over the forecast period due to a rise in the outsourcing of clinical trials in this region



Contents

CHAPTER 1. METHODOLOGY AND SCOPE

- 1.1. Market Segmentation & Scope
 - 1.1.1. Therapeutic Areas
 - 1.1.2. Phase
 - 1.1.3. End Use
 - 1.1.4. Regional scope
 - 1.1.5. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
 - 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
 - 1.4.1. Data analysis models
- 1.5. Market Formulation & Validation
- 1.6. Model Details
 - 1.6.1. Commodity flow analysis (Model 1)
 - 1.6.1.1. Approach 1: Commodity flow approach
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
 - 1.9.1. Objective
 - 1.9.2. Objective

CHAPTER 2. EXECUTIVE SUMMARY

2.1. Market Outlook

CHAPTER 3. CLINICAL TRIAL INVESTIGATIVE SITE NETWORK MARKET VARIABLES, TRENDS & SCOPE

- 3.1. Market Lineage Outlook
 - 3.1.1. Parent market outlook
 - 3.1.2. Related/ancillary market outlook



- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Market Dynamics
 - 3.3.1. Market driver analysis
- 3.3.1.1. Increasing partnership amongst contract research sites, thereby boosting the growth of clinical trial investigative site networks
- 3.3.1.2. High prevalence of diseases worldwide contributing to the demand for clinical research
 - 3.3.1.3. Globalization of clinical trials
 - 3.3.2. Market restraint analysis
 - 3.3.2.1. Communication errors between sites and principal investigators
 - 3.3.2.2. Complexities in clinical studies and research procedures
- 3.4. Clinical Trial Investigative Site Network Market Analysis Tools
 - 3.4.1. Industry Analysis Porter's
 - 3.4.2. PESTEL Analysis
 - 3.4.3. Major Deals & Strategic Alliances Analysis
- 3.5. Covid-19 Impact Analysis and Reformation Strategies

CHAPTER 4. CLINICAL TRIAL INVESTIGATIVE SITE NETWORK MARKET: THERAPEUTIC AREAS ESTIMATES & TREND ANALYSIS

- 4.1. Definitions and Scope
- 4.2. Clinical Trial Investigative Site Network Market Share, 2021 & 2030
 - 4.2.1. Oncology
 - 4.2.1.1. Oncology market estimates and forecast 2018 to 2030 (USD Million)
 - 4.2.2. Cardiology
 - 4.2.2.1. Cardiology market estimates and forecast 2018 to 2030 (USD Million)
 - 4.2.3. CNS
 - 4.2.3.1. CNS market estimates and forecast 2018 to 2030 (USD Million)
 - 4.2.4. Pain Management
 - 4.2.4.1. Pain management market estimates and forecast 2018 to 2030 (USD Million)
 - 4.2.5. Endocrine
 - 4.2.5.1. Endocrine market estimates and forecast 2018 to 2030 (USD Million)
 - 4.2.6. Others
 - 4.2.6.1. Others market estimates and forecast 2018 to 2030 (USD Million)

CHAPTER 5. CLINICAL TRIAL INVESTIGATIVE SITE NETWORK MARKET: PHASE ESTIMATES & TREND ANALYSIS

5.1. Definitions and Scope



- 5.2. Clinical Trial Investigative Site Network Market Share, 2021 & 2030
 - 5.2.1. Phase I
 - 5.2.1.1. Phase I market estimates and forecast 2018 to 2030 (USD Million)
 - 5.2.2. Phase II
 - 5.2.2.1. Phase II market estimates and forecast 2018 to 2030 (USD Million)
 - 5.2.3. Phase III
 - 5.2.3.1. Phase III market estimates and forecast 2018 to 2030 (USD Million)
 - 5.2.4. Phase IV
 - 5.2.4.1. Phase IV market estimates and forecast 2018 to 2030 (USD Million)

CHAPTER 6. CLINICAL TRIAL INVESTIGATIVE SITE NETWORK MARKET: END-USE ESTIMATES & TREND ANALYSIS

- 6.1. Definitions and Scope
- 6.2. Clinical Trial Investigative Site Network Market Share, 2021 & 2030
 - 6.2.1. Sponsor
 - 6.2.1.1. Sponsors market estimates and forecast 2018 to 2030 (USD Million)
 - 6.2.2. CRO
 - 6.2.2.1. CRO market estimates and forecast 2018 to 2030 (USD Million)

CHAPTER 7. CLINICAL TRIAL INVESTIGATIVE SITE NETWORK MARKET: REGIONAL ESTIMATES & TREND ANALYSIS

- 7.1. Regional market share analysis, 2021 & 2030
- 7.2. North America
 - 7.2.1. U.S.
 - 7.2.1.1. U.S. Market estimates and forecast, 2018 2030
 - 7.2.2. Canada
 - 7.2.2.1. Canada Market estimates and forecast, 2018 2030
- 7.3. Europe
 - 7.3.1. U.K.
 - 7.3.1.1. U.K. Market estimates and forecast, 2018 2030
 - 7.3.2. Germany
 - 7.3.2.1. Germany Market estimates and forecast, 2018 2030
 - 7.3.3. France
 - 7.3.3.1. France Market estimates and forecast, 2018 2030
 - 7.3.4. Italy
 - 7.3.4.1. Italy Market estimates and forecast, 2018 2030
 - 7.3.5. Spain



- 7.3.5.1. Spain Market estimates and forecast, 2018 2030
- 7.3.6. The Netherlands
 - 7.3.6.1. The Netherlands Market estimates and forecast, 2018 2030
- 7.3.7. Sweden
 - 7.3.7.1. Sweden Market estimates and forecast, 2018 2030
- 7.3.8. Switzerland
- 7.3.8.1. Switzerland Market estimates and forecast, 2018 2030
- 7.3.9. Russia
 - 7.3.9.1. Russia Market estimates and forecast, 2018 2030
- 7.3.10. Belgium
 - 7.3.10.1. Belgium Market estimates and forecast, 2018 2030
- 7.4. Asia Pacific
 - 7.4.1. Japan
 - 7.4.1.1. Japan Market estimates and forecast, 2018 2030
 - 7.4.2. China
 - 7.4.2.1. China Market estimates and forecast, 2018 2030
 - 7.4.3. India
 - 7.4.3.1. India Market estimates and forecast, 2018 2030
 - 7.4.4. Australia
 - 7.4.4.1. Australia Market estimates and forecast, 2018 2030
 - 7.4.5. South Korea
 - 7.4.5.1. South Korea Market estimates and forecast, 2018 2030
 - 7.4.6. Thailand
 - 7.4.6.1. Thailand Market estimates and forecast, 2018 2030
 - 7.4.7. Malaysia
 - 7.4.7.1. Malaysia Market estimates and forecast, 2018 2030
 - 7.4.8. New Zealand
 - 7.4.8.1. New Zealand Market estimates and forecast, 2018 2030
 - 7.4.9. Philippines
 - 7.4.9.1. Philippines Market estimates and forecast, 2018 2030
 - 7.4.10. Singapore
 - 7.4.10.1. Singapore Market estimates and forecast, 2018 2030
- 7.5. Latin America
 - 7.5.1. Brazil
 - 7.5.1.1. Brazil Market estimates and forecast, 2018 2030
 - 7.5.2. Mexico
 - 7.5.2.1. Mexico Market estimates and forecast, 2018 2030
 - 7.5.3. Argentina
 - 7.5.3.1. Argentina Market estimates and forecast, 2018 2030



- 7.5.4. Colombia
 - 7.5.4.1. Colombia Market estimates and forecast, 2018 2030
- 7.5.5. Chile
 - 7.5.5.1. Chile Market estimates and forecast, 2018 2030
- 7.6. MEA
 - 7.6.1. South Africa
 - 7.6.1.1. South Africa Market estimates and forecast, 2018 2030
 - 7.6.2. Saudi Arabia
 - 7.6.2.1. Saudi Arabia Market estimates and forecast, 2018 2030
 - 7.6.3. UAE
 - 7.6.3.1. UAE Market estimates and forecast, 2018 2030
 - 7.6.4. Israel
 - 7.6.4.1. Israel Market estimates and forecast, 2018 2030
 - 7.6.5. Egypt
 - 7.6.5.1. Egypt Market estimates and forecast, 2018 2030

CHAPTER 8. COMPETITIVE ANALYSIS

- 8.1. Recent Developments & Impact Analysis, By Key Market Participant
- 8.2. Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
- 8.3. Participant Categorization
- 8.4. Vendor Landscape
 - 8.4.1. List of Key Service Providers
 - 8.4.2. Market Differentiators
- 8.5. Market share analysis

CHAPTER 9. COMPETITIVE LANDSCAPE

- 9.1. Company Profiles
 - 9.1.1. ICON plc
 - 9.1.1.1. Company overview
 - 9.1.1.2. Product benchmarking
 - 9.1.1.3. Strategic initiatives
 - 9.1.2. MERIDIAN CLINICAL RESEARCH
 - 9.1.2.1. Company overview
 - 9.1.2.2. Financial performance
 - 9.1.2.3. Product benchmarking
 - 9.1.2.4. Strategic initiatives



- 9.1.3. IQVIA Inc.
 - 9.1.3.1. Company overview
 - 9.1.3.2. Financial performance
 - 9.1.3.3. Product benchmarking
 - 9.1.3.4. Strategic initiatives
- 9.1.4. Clinedge
 - 9.1.4.1. Company overview
 - 9.1.4.2. Financial performance
 - 9.1.4.3. Product benchmarking
 - 9.1.4.4. Strategic initiatives
- 9.1.5. WCG
 - 9.1.5.1. Company overview
 - 9.1.5.2. Financial performance
 - 9.1.5.3. Product benchmarking
 - 9.1.5.4. Strategic initiatives
- 9.1.6. ClinChoice
 - 9.1.6.1. Company overview
 - 9.1.6.2. Financial performance
 - 9.1.6.3. Product benchmarking
 - 9.1.6.4. Strategic initiatives
- 9.1.7. Access Clinical Research
 - 9.1.7.1. Company overview
 - 9.1.7.2. Financial performance
 - 9.1.7.3. Product benchmarking
 - 9.1.7.4. Strategic initiatives
- 9.1.8. FOMAT Medical Research INC.
 - 9.1.8.1. Company overview
 - 9.1.8.2. Financial performance
 - 9.1.8.3. Product benchmarking
 - 9.1.8.4. Strategic initiatives
- 9.1.9. SGS SA
 - 9.1.9.1. Company overview
 - 9.1.9.2. Financial performance
 - 9.1.9.3. Product benchmarking
 - 9.1.9.4. Strategic initiatives
- 9.1.10. KV Clinical
 - 9.1.10.1. Company overview
 - 9.1.10.2. Financial performance
 - 9.1.10.3. Product benchmarking



- 9.1.10.4. Strategic initiatives
- 9.1.11. SMO-Pharmina
 - 9.1.11.1. Company overview
 - 9.1.11.2. Financial performance
 - 9.1.11.3. Product benchmarking
 - 9.1.11.4. Strategic initiatives
- 9.1.12. Xylem Clinical Research
 - 9.1.12.1. Company overview
 - 9.1.12.2. Financial performance
 - 9.1.12.3. Product benchmarking
 - 9.1.12.4. Strategic initiatives



List Of Tables

LIST OF TABLES

Table 1 List of secondary sources
Table 2 List of Abbreviations



List Of Figures

LIST OF FIGURES

- Fig. 1 Market research process
- Fig. 2 Information procurement
- Fig. 3 Primary research pattern
- Fig. 4 Market research approaches
- Fig. 5 Value-chain-based sizing & forecasting
- Fig. 6 QFD modeling for market share assessment
- Fig. 7 Market formulation & validation
- Fig. 8 Commodity flow analysis
- Fig. 9 Volume Price Analysis
- Fig. 10 Clinical Trial Investigative Site Network market snapshot (2021)
- Fig. 11 Clinical Trial Investigative Site Network market segmentation
- Fig. 12 Market driver relevance analysis (Current & future impact)
- Fig. 13 Market restraint relevance analysis (Current & future impact)
- Fig. 14 Penetration & growth prospect mapping
- Fig. 15 Porter's five forces analysis
- Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
- Fig. 17 Clinical Trial Investigative Site Network market therapeutic area outlook:

Segment dashboard

- Fig. 18 Clinical Trial Investigative Site Network market: therapeutic area movement analysis
- Fig. 19 Oncology market, 2018 2030 (USD Million)
- Fig. 20 Cardiology market, 2018 2030 (USD Million)
- Fig. 21 CNS market, 2018 2030 (USD Million)
- Fig. 22 Pain Management market, 2018 2030 (USD Million)
- Fig. 23 Endocrine market, 2018 2030 (USD Million)
- Fig. 24 Others market, 2018 2030 (USD Million)
- Fig. 25 Clinical Trial Investigative Site Network market phase outlook: Segment dashboard
- Fig. 26 Clinical Trial Investigative Site Network market phase outlook: Segment dashboard
- Fig. 27 Phase I market, 2018 2030 (USD Million)
- Fig. 28 Phase II market, 2018 2030 (USD Million)
- Fig. 29 Phase III market, 2018 2030 (USD Million)
- Fig. 30 Phase IV market, 2018 2030 (USD Million)
- Fig. 31 Clinical Trial Investigative Site Network market end use outlook: Segment



dashboard

- Fig. 32 Clinical Trial Investigative Site Network market: End use movement analysis
- Fig. 33 Spionsor market, 2018 2030 (USD Million)
- Fig. 34 CRO market, 2018 2030 (USD Million)
- Fig. 35 Regional market: Key takeaways
- Fig. 36 Regional outlook, 2021 & 2030
- Fig. 37 North America market, 2018 2030 (USD Million)
- Fig. 38 U.S. market, 2018 2030 (USD Million)
- Fig. 39 Canada market, 2018 2030 (USD Million)
- Fig. 40 Europe market, 2018 2030 (USD Million)
- Fig. 41 U.K. market, 2018 2030 (USD Million)
- Fig. 42 Germany market, 2018 2030 (USD Million)
- Fig. 43 France market, 2018 2030 (USD Million)
- Fig. 44 Italy market, 2018 2030 (USD Million)
- Fig. 45 Spain market, 2018 2030 (USD Million)
- Fig. 46 The Netherlands market, 2018 2030 (USD Million)
- Fig. 47 Belgium market, 2018 2030 (USD Million)
- Fig. 48 Sweden market, 2018 2030 (USD Million)
- Fig. 49 Switzerland market, 2018 2030 (USD Million)
- Fig. 49 Russia market, 2018 2030 (USD Million)
- Fig. 51 Asia Pacific market, 2018 2030 (USD Million)
- Fig. 52 China market, 2018 2030 (USD Million)
- Fig. 53 India market, 2018 2030 (USD Million)
- Fig. 54 Japan market, 2018 2030 (USD Million)
- Fig. 55 Australia market, 2018 2030 (USD Million)
- Fig. 56 South Korea market, 2018 2030 (USD Million)
- Fig. 57 Malaysia market, 2018 2030 (USD Million)
- Fig. 58 New Zealand market, 2018 2030 (USD Million)
- Fig. 59 Philippines market, 2018 2030 (USD Million)
- Fig. 60 Thailand market, 2018 2030 (USD Million)
- Fig. 61 Singapore market, 2018 2030 (USD Million)
- Fig. 62 South Korea market, 2018 2030 (USD Million)
- Fig. 63 Latin America market, 2018 2030 (USD Million)
- Fig. 64 Brazil market, 2018 2030 (USD Million)
- Fig. 65 Mexico market, 2018 2030 (USD Million)
- Fig. 66 Argentina market, 2018 2030 (USD Million)
- Fig. 67 Colombia market, 2018 2030 (USD Million)
- Fig. 68 Chile market, 2018 2030 (USD Million)
- Fig. 69 MEA market, 2018 2030 (USD Million)



Fig. 70 South Africa market, 2018 - 2030 (USD Million)

Fig. 71 Saudi Arabia market, 2018 - 2030 (USD Million)

Fig. 72 Israel market, 2018 - 2030 (USD Million)

Fig. 73 Egypt market, 2018 - 2030 (USD Million)

Fig. 74 UAE market, 2018 - 2030 (USD Million)



I would like to order

Product name: Clinical Trial Investigative Site Network Market Size, Share & Trends Analysis Report By

Therapeutic Areas (Oncology, CNS), By Phase (Phase I, III), By End-use (Sponsor,

CRO), By Region, And Segment Forecasts, 2022 - 2030

Product link: https://marketpublishers.com/r/C1EDABC88200EN.html

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/C1EDABC88200EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

| First name: | |
|---------------|---------------------------|
| Last name: | |
| Email: | |
| Company: | |
| Address: | |
| City: | |
| Zip code: | |
| Country: | |
| Tel: | |
| Fax: | |
| Your message: | |
| | |
| | |
| | |
| | **All fields are required |
| | Custumer signature |
| | |
| | |

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970